礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参_老虎社区_美港股上老虎

礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参

每日经济新闻03-12 01:00

｜2026年3月12日星期四｜　　NO.1 恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官　　3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。2023年5月至2025年1月，他还兼任恒瑞医药生物药制造事业部总经理，主要负责协调...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2618883922?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-12 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618883922","market":"hk","top_or_hot":-1,"title":"礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参","media":"每日经济新闻","content":"<div>\n<p>｜2026年3月12日星期四｜　　NO.1 恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官　　3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。2023年5月至2025年1月，他还兼任恒瑞医药生物药制造事业部总经理，主要负责协调...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603123669204642.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来宣布未来十年投资30亿美元扩展在华供应链产能；恒瑞前高管王宏伟加入康宁杰瑞任首席技术官｜医药早参\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 01:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603123669204642.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>｜2026年3月12日星期四｜　　NO.1 恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官　　3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。2023年5月至2025年1月，他还兼任恒瑞医药生物药制造事业部总经理，主要负责协调...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603123669204642.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131342.USD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603123669204642.html","article_id":"2618883922","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603123669204642.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618883922","pubTimestamp":1773248442,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"｜2026年3月12日星期四｜NO.1恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LLY":"礼来","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4588":"碎股","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","09966":"康宁杰瑞制药-B","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","ELIL":"2倍做多LLY ETF-Direxion","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","ELIS":"1倍做空LLY ETF-Direxion","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","BK1161":"生物科技","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0238689110.USD":"贝莱德环球动力股票基金","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK1574":"生物医药B类股","LU0385154629.USD":"贝莱德营养科学基金A2","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4599":"减肥药","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2473716301.USD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMF\" (USD) INC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2272731782.SGD":"Allianz Global Intelligent Cities AM Dis H2-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4007":"制药","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","BK1515":"抗疫概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LLII":"REX LLY Growth & Income ETF","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2272731865.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AM\" (HKD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LLYX":"2倍做多LLY ETF-Defiance","LU2322448791.USD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMG\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LLYZ":"2倍做空LLY ETF-Defiance","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1992135399.USD":"Allianz Global Intelligent Cities AT Acc USD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4148":"电子元件","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","BK4581":"高盛持仓","LU0122379950.USD":"贝莱德世界健康科学A2","BK4512":"苹果概念","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4534":"瑞士信贷持仓","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","BK4516":"特朗普概念","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","LU2322448957.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMG\" (HKD) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0079474960.USD":"联博美国增长基金A","LU0882574055.USD":"富达全球健康医疗A ACC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD"},"translate_title":"Eli Lilly announced that it will invest $3 billion in the next ten years to expand supply chain capacity in China; Former Hengrui executive Wang Hongwei joins Alphamab as CTO | Pharmaceutical Morning Ginseng","themeId":"6afbb4a2a5e710528ea777914b8996d7","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1.85,"LLII":0.6,"LLYZ":0.6,"ELIS":0.6,"LLY":1.93,"LLYX":0.6,"09966":1.88,"ELIL":0.6},"content_text":"｜2026年3月12日星期四｜　　NO.1 恒瑞前高管王宏伟加入康宁杰瑞生物制药，任首席技术官　　3月11日，康宁杰瑞生物制药发布自愿公告，正式宣布委任王宏伟博士为公司首席技术官，全面负责工艺开发、分析开发、生产和质量相关工作。王宏伟的职业生涯起步于恒瑞医药，于2011年7月至2018年7月任恒瑞医药高级研究员。2023年5月至2025年1月，他还兼任恒瑞医药生物药制造事业部总经理，主要负责协调生物制品开发与制造运营。　　点评：康宁杰瑞委任王宏伟为CTO，全面统筹生产与质量体系，将强化公司产业化转化能力，加速核心管线落地与全球商业化进程，夯实全产业链竞争力。　　NO.2 礼来宣布未来十年投资30亿美元，扩展在华供应链产能　　3月11日，礼来宣布计划未来十年累计投资30亿美元，全面扩展在华供应链产能，打造口服固体制剂本土生产与供应体系，着力布局首个申报注册的口服小分子GLP-1受体激动剂Orforglipron的生产能力。同时，公司宣布与康龙化成达成战略合作，拟投2亿美元支持其技术建设。　　点评：礼来未来十年累计投资30亿美元扩产在华供应链，同步投资2亿美元与康龙化成合作，彰显了对中国GLP-1市场的长期看好，加速核心管线落地、提升本地化供应能力，推动全球供应链深度本土化，利好产业链协同与产能升级。　　NO.3 和誉医药FGFR2/3抑制剂获美国FDA授予罕见儿科疾病资格　　和誉医药3月11日宣布，其自主研发的高选择性小分子FGFR2/3抑制剂ABSK061治疗软骨发育不全（ACH）适应证获得美国FDA授予的罕见儿科疾病（RPD）资格认定。　　点评：和誉医药FGFR2/3抑制剂罕见儿科疾病资格，靶向软骨发育不全精准靶点，该资格可助力加速审评并获取优先审评券，彰显公司在儿童罕见病创新药研发的领先实力与国际化布局优势。　　NO.4 微芯生物：首次回购约3.2万股　　微芯生物3月11日发布公告称，2026年3月11日，公司通过上海证券交易所交易系统以集中竞价交易方式首次回购公司股份约3.2万股，占公司总股本的比例为0.01%，回购成交的价格为31.11元/股，支付的资金总额约为人民币100万元。　　点评：微芯生物实施股份回购，用真金白银传递对公司未来发展的信心与价值认可，有利于稳定市场预期、维护中小投资者利益。同时回购股份用于股权激励或员工持股计划，有助于完善长效激励机制、绑定核心人才利益。（文章来源：每日经济新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}